Immunoteràpies cel·lulars pel càncer
Publicacions destacades
-
Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?
Guedan, S; Luu, M; Ammar, D; Barbao, P; Bonini, C;(...)Rodriguez-Madoz, JR; Ruggiero, E; Themeli, M; Hudecek, M; Marchiq, I.Referència:Journal For Immunotherapy Of Cancer 2022.
-
An NK-like CAR T cell transition in CAR T cell dysfunction
Good, CR; Aznar, MA; Kuramitsu, S; Samareh, P; Agarwal, S;(...)Albelda, SM; Lanier, LL; Young, RM; Berger, SL; June, CH.Referència:Cell 2021.
-
Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells
Irving, M; Lanitis, E; Migliorini, D; Ivics, Z; Guedan, S;Referència:Human Gene Therapy 2021.
-
CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy
Rodriguez-Garcia A; Lynn RC; Poussin M; Eiva MA; Shaw LC;(...)Minutolo NG; Casado-Medrano V; Lopez G; Matsuyama T; Powell DJ.Referència:Nature Communications 2021.
-
Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability
Guedan S; Madar A; Casado-Medrano V; Shaw C; Wing A;Liu F; Young RM; June CH; Posey AD .Referència:Journal Of Clinical Investigation 2020.
-
Analysis of car-mediated tonic signaling.
Hugo Calderon; Maksim Mamonkin; Sonia Guedan;Referència:Methods In Molecular Biology 2020.
-
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
Guedan, Sonia; Posey, Avery D., Jr.; Shaw, Carolyn; Wing, Anna; Da, Tong;(...)Lacey, Simon F.; Scholler, John; Keith, Brian; Young, Regina M.; June, Carl H.;.Referència:Jci Insight 2018.
-
Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
Wing A; Fajardo CA; Posey AD; Shaw C; Da T;Young RM; Alemany R; June CH; Guedan S .Referència:Cancer Immunology Research 2018.